Real-World Experience of Venetoclax Combination Therapy in Patients with Acute Myeloid Leukemia (AML): A Single-Institution Retrospective Study in a Middle-Income Country
Natalia Aránguiz, Ximena Valladares, Javiera Donoso, Sebastian Ignacio Ewoldt et autres
Introduction Venetoclax (VEN) combined with hypomethylating (HMA) agents or intensive chemotherapy (IC) has demonstrated high remission rates, good disease control, and high allogeneic stem cell transplantation (allo-SCT) rates in patients with acute myeloid leukemia (AML) compared to chemotherapy alone. Real-world data are …
cl (code pays fourni par la source)
0 citations
Blood